Press Releases Keyword Search Year None20262025202420232022202120202019201820172016201520142013 July 27, 2023 Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization July 26, 2023 Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update July 25, 2023 Editas Medicine Reports Inducement Grant to New Chief Scientific Officer July 24, 2023 Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer June 14, 2023 Editas Medicine Announces Pricing of Offering of Common Stock June 14, 2023 Editas Medicine Announces Offering of Common Stock June 9, 2023 Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial June 6, 2023 Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia May 18, 2023 Editas Medicine Reports Inducement Grant to New Chief Financial Officer May 16, 2023 Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last »
July 27, 2023 Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 26, 2023 Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 24, 2023 Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
June 9, 2023 Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
June 6, 2023 Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
